ISJETs: Learn the terminology and lead in your own disease type. Im very excited to say our first paper on INvestigator-assigned subjective or judgementl efficacy and toxicity reporting is now in press at JTO.
Comments
Log in with your Bluesky account to leave a comment
This has been in our faces for decades and waiting to be called out. Investogators in clinical trials dress efficacy and toxicty objective results in subjective clothing. How can an MD call something tolerable if they didnt experience it? If they didnt ask the patients about tolerability per se?
Why should anything less than a grade 3 toxicity be considered acceptable and why, when grade 1 and 2 toxicities can be so different, are they grouped?
The need to remedy this approach has been percolating in several tumor types and I urge colelagues to replicate this simple analysis in their disease type and track it over time and publish it.
Comments